A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
This study is a multicenter, open-label Phase Ib/II clinical trial to observe and evaluate the safety, tolerability and pharmacokinetics of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer mechanical characterization and preliminary evaluation of the efficacy of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer.
Recurrent Ovarian Cancer
DRUG: Bevacizumab； HRS-1167
The number of subjects with dose-limiting toxicity (DLT), From first dose of study treatment until the end of Cycle 1（up to 21 days）|Determination of Recommended Phase II dose (RP2D), From first dose of study treatment until the end of Cycle 1（up to 21 days）
Objective Response Rate (ORR), The percentage of participants with a confirmed CR or PR according to RECIST v1.1 criteria., From time of first dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)]|Disease Control Rate (DCR), The percentage of participants who have a best objective response of confirmed CR or PR or who have SD for at least 15 weeks after start of treatment, From time of first dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)|Duration of Response (DoR), The time from the date of first response until date of disease progression or death in the absence of disease progression., From time of first dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)|Progression free Survival (PFS), Progression-free survival is defined as the time from the start of treatment until the date of objective disease progression or death, From time of fist dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)|Overall Survival (OS), The time until death due to any cause., From time of first dose of HRS-1167 or Bevacizumab until the date of death (up to 24 months)|Time To Response(TTR), Time from C1D1 to complete or partial response, according to RECIST v1.1 criteria., From time of first dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)
This study is a multicenter, open-label Phase Ib/II clinical trial to observe and evaluate the safety, tolerability and pharmacokinetics of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer mechanical characterization and preliminary evaluation of the efficacy of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer.